NO20062303L - Pyrazinderivater og farmasoytisk anvendelse derav - Google Patents

Pyrazinderivater og farmasoytisk anvendelse derav

Info

Publication number
NO20062303L
NO20062303L NO20062303A NO20062303A NO20062303L NO 20062303 L NO20062303 L NO 20062303L NO 20062303 A NO20062303 A NO 20062303A NO 20062303 A NO20062303 A NO 20062303A NO 20062303 L NO20062303 L NO 20062303L
Authority
NO
Norway
Prior art keywords
disease
dementia
pharmaceutical use
pyrazine derivatives
parkinson
Prior art date
Application number
NO20062303A
Other languages
English (en)
Inventor
Satoshi Yonishi
Satoshi Aoki
Yuji Matsushima
Atsusi Akahane
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003905895A external-priority patent/AU2003905895A0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20062303L publication Critical patent/NO20062303L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Pyrazinderivat med følgende formel (I): eller et salt derav. Pyrazin-forbindelsen (I) og et salt derav i den foreliggende oppfinnelsen er adenosin-antagonister og er nyttig for å forhindre og/eller behandle depresjon, demens (f.eks. Alzheimers sykdom, cerebrovaskulær demens, demens assosiert med Parkinsons sykdom osv.), Parkinsons sykdom, angst, smerte, cerebrovaskulaer sykdom (f.eks. slagtilfelle osv.), hjertesvikt og lignende tilstander.
NO20062303A 2003-10-27 2006-05-22 Pyrazinderivater og farmasoytisk anvendelse derav NO20062303L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003905895A AU2003905895A0 (en) 2003-10-27 Pyrazine Derivative and Pharmaceutical use Thereof
AU2004902764A AU2004902764A0 (en) 2004-05-24 Pyrazine Derivative and Pharmaceutical Use Thereof
PCT/JP2004/016193 WO2005040151A1 (en) 2003-10-27 2004-10-25 Pyrazine derivatives and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NO20062303L true NO20062303L (no) 2006-07-19

Family

ID=34523512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062303A NO20062303L (no) 2003-10-27 2006-05-22 Pyrazinderivater og farmasoytisk anvendelse derav

Country Status (11)

Country Link
US (1) US7407961B2 (no)
EP (1) EP1678160A1 (no)
JP (1) JP4650419B2 (no)
KR (1) KR20060123208A (no)
AR (1) AR046200A1 (no)
BR (1) BRPI0415863A (no)
CA (1) CA2543644A1 (no)
NO (1) NO20062303L (no)
RU (1) RU2006118325A (no)
TW (1) TW200526620A (no)
WO (1) WO2005040151A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005252160A1 (en) 2004-04-13 2005-12-22 Astellas Pharma Inc. Polycyclic pyrazines as potassium ion channel modulators
AU2005322338B2 (en) * 2004-12-27 2011-06-09 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
JP2009541323A (ja) * 2006-06-22 2009-11-26 マリンクロット インコーポレイテッド 拡張された共役を有するピラジン誘導体およびその使用
FR2945609B1 (fr) * 2009-05-12 2013-03-29 Avancis Gmbh & Co Kg Dispositif de fixation et procede de montage de modules solaires.
RU2543484C2 (ru) * 2009-10-30 2015-03-10 Янссен Фармацевтика Нв Пиразины для использования в качестве модуляторов дельта-опиоидных рецепторов
SI2531492T1 (sl) 2010-02-05 2016-08-31 Heptares Therapeutics Limited Derivati 1,2,4-triazin-4-amina
RU2676694C9 (ru) 2013-01-23 2019-06-25 Альдейра Терапьютикс, Инк. Заболевания, связанные с токсичным альдегидом, и их лечение
CA2967944C (en) * 2014-11-18 2020-11-17 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
JP6947406B2 (ja) 2015-08-21 2021-10-13 アルデイラ セラピューティクス， インコーポレイテッド 重水素化化合物およびその使用
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
EP4302834A2 (en) 2016-07-12 2024-01-10 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
EP3596040B1 (en) 2017-03-16 2023-10-11 Aldeyra Therapeutics, Inc. Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof
CA3070273A1 (en) * 2017-07-18 2019-01-24 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2019018583A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
SG11202001282UA (en) 2017-09-07 2020-03-30 Revolution Medicines Inc Shp2 inhibitor compositions and methods for treating cancer
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CR20200578A (es) 2018-05-01 2021-02-22 Revolution Medicines Inc Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CA3107365A1 (en) * 2018-08-17 2020-02-20 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Pyrazine compounds and uses thereof
CN111377906B (zh) * 2018-12-28 2022-09-02 四川科伦博泰生物医药股份有限公司 取代的吡嗪化合物及其制备方法和用途
CA3126702A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150677A1 (en) * 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
AU2020207951A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2021146629A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2021146631A1 (en) * 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072746A (en) * 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
US4313951A (en) * 1979-11-26 1982-02-02 Sterling Drug Inc. 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor
CA2209465C (en) * 1996-07-11 2008-04-29 Lonza Ag Process for preparing 3-alkoxy-5-alkylpyrazin-2-amines
AU1909200A (en) * 1998-11-04 2000-05-22 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6995161B2 (en) * 2000-02-16 2006-02-07 Neurogen Corporation Substituted arylpyrazines
BR0108611A (pt) * 2000-02-25 2003-05-06 Hoffmann La Roche Moduladores de receptor de adenosina
JP4251868B2 (ja) * 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
TWI330183B (no) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2467870A1 (en) * 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Substituted aryl 1,4-pyrazine derivatives
AU2002950853A0 (en) * 2002-08-19 2002-09-12 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compound and pharmaceutical use thereof
US7179807B2 (en) * 2002-08-20 2007-02-20 Neurogen Corporation 5-substituted-2-arylpyrazines

Also Published As

Publication number Publication date
KR20060123208A (ko) 2006-12-01
BRPI0415863A (pt) 2007-01-09
TW200526620A (en) 2005-08-16
US20050113387A1 (en) 2005-05-26
JP2007510620A (ja) 2007-04-26
US7407961B2 (en) 2008-08-05
JP4650419B2 (ja) 2011-03-16
WO2005040151A1 (en) 2005-05-06
RU2006118325A (ru) 2007-12-10
CA2543644A1 (en) 2005-05-06
AR046200A1 (es) 2005-11-30
EP1678160A1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
CY1119971T1 (el) Αναστολεις gsk-3
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2005095384A8 (en) Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
EA200401114A2 (ru) Замещённые гидроксиэтиламины
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
CY1105341T1 (el) Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
TW200736255A (en) 5-(Substituted)-pyrazolopiperidines
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
EP1817311A4 (en) 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS AS BETA SEKTRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
NO20055205L (no) 4-(2-fcnylsulfanyl-fenyl)-1,2,3,6-tydropyridinderivater som serotoniniopptaksinhibitorer
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
WO2004022540A3 (en) Pyridazinone and pyridone derivatives as adenosine antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application